West Pharma (WST) Tops Q4 EPS by 1c, Revenues Miss; Offers FY19 EPS Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
West Announces Fourth-Quarter and Full-Year 2018 Results
February 14, 2019 6:00 AM ESTEXTON, Pa., Feb. 14, 2019 /PRNewswire/ --Â West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2018 and provided financial guidance for full-year 2019.Â
Executive Summary
Fourth-quarter 2018 reported net sales were $422.5 million, representing growth of 1.7% over last year's period and constant-currency, organic sales growth of 3.6%. Fourth-quarter 2018 reported net sales included a... More


